Erasca (ERAS) Change in Accured Expenses (2020 - 2026)
Erasca posted quarterly Change in Accured Expenses of -$3.3 million for Q1 2026, up 59.17% year-on-year from -$2.1 million in Q1 2025, and down 295.75% on a QoQ basis from $1.7 million in Q4 2025.
Erasca (ERAS) has 7 years of Change in Accured Expenses data on file, last reported at -$3.3 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 59.17% year-over-year to -$3.3 million; the trailing twelve-month figure through Mar 2026 stood at $969000.0 (down 51.93% YoY), and the FY2025 full-year result was -$3.8 million, down 158.91% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$3.3 million, down from $1.7 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $5.5 million in Q3 2024 and bottomed at -$8.0 million in Q1 2025.
- The 5-year median for Change in Accured Expenses is $1.3 million (2024), against an average of $122117.6.
- The widest annual swing landed in 2022, when Change in Accured Expenses slumped 1135.69%; it then surged 240.13% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $2.1 million in 2022, then slumped by 54.27% to $952000.0 in 2023, then soared by 240.13% to $3.2 million in 2024, then tumbled by 48.42% to $1.7 million in 2025, then sank by 295.75% to -$3.3 million in 2026.
- The last three Change in Accured Expenses figures came in at -$3.3 million (Q1 2026), $1.7 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.27 Mn |
| Mar 31, 2026 | -3.27 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.19 Mn |
| Sep 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | -8.01 Mn |
| Mar 31, 2025 | -8.01 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 5.47 Mn |
| Sep 30, 2024 | 5.47 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | -3.63 Mn |
| Mar 31, 2024 | -3.63 Mn |
| Dec 31, 2023 | 952,000.00 |
| Dec 31, 2023 | 952,000.00 |
| Sep 30, 2023 | 2.47 Mn |
| Sep 30, 2023 | 2.47 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Mar 31, 2023 | -4.36 Mn |
| Mar 31, 2023 | -4.36 Mn |
| Dec 31, 2022 | 2.08 Mn |
| Dec 31, 2022 | 2.08 Mn |
| Sep 30, 2022 | 3.58 Mn |
| Sep 30, 2022 | 3.58 Mn |
| Jun 30, 2022 | 3.01 Mn |
| Jun 30, 2022 | 3.01 Mn |
| Mar 31, 2022 | -3.66 Mn |
| Mar 31, 2022 | -3.66 Mn |
| Dec 31, 2021 | 4.69 Mn |
| Dec 31, 2021 | 4.69 Mn |
| Sep 30, 2021 | 2.19 Mn |
| Sep 30, 2021 | 2.19 Mn |
| Jun 30, 2021 | 4.63 Mn |
| Jun 30, 2021 | 4.63 Mn |
| Mar 31, 2021 | 353,000.00 |
| Mar 31, 2021 | 353,000.00 |
| Dec 31, 2020 | 1.25 Mn |
| Dec 31, 2020 | 1.25 Mn |
| Sep 30, 2020 | 1.99 Mn |
| Sep 30, 2020 | 1.99 Mn |